Continuous intravenous infusion therapy with cyclosporine A for rapidly progressive interstitial pneumonia associated with dermatomyositis and polymyositis

Continuous intravenous infusion therapy with cyclosporine A for rapidly progressive interstitial pneumonia associated with dermatomyositis and polymyositis - Continuous intravenous infusion therapy with cyclosporine A for rapidly progressive interstitial pneumonia associated with dermatomyositis and polymyositis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001866

Enrollment

Registered

2009-04-10

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatomyositis or polymyositis with interstitial pneumonia

Interventions

(1)The patients are initially treated with methylprednisolone (m-PSL) pulse (1000 mg daily for three days) followed by oral prednisolone (1mg/kg daily). (2)Continuous intravenous CyA (2 mg/kg daily f

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: In addition of fulfilling diagnostic criteria for DM/PM or clinically amyopathic DM and the presence of IP on chest X-ray and/or CT, one or more of the following clinical findings are necessary ; (1) %VC is lower than 80%, (2) % DLCO is lower than 70%, (3) acute respiratory symptoms (dyspnea, dry cough), (4) PaO2 is lower than 70mmHg.

Exclusion criteria

Exclusion criteria: We exclude patients with active infectious disease, severe renal dysfunction and malignancy.

Design outcomes

Primary

Measure	Time frame
Clinical symptoms, Respiratory functional evaluation, Chest CT and X-ray, Blood examinations	—

Secondary

Measure	Time frame
To evaluate long-term prognosis To establish an effective therapeutic strategy	—

Countries

Japan

Contacts

Public ContactYasuhiro Shimojima

Shinshu University School of Medicine Department of Neurology and Rheumatology

yshimoji@shinshu-u.ac.jp0263-37-2673

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026